NASDAQ:ALGS Aligos Therapeutics - ALGS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.32 0.00 (0.00%) (As of 03/17/2023 06:55 PM ET) Add Compare Share Share Today's Range$1.23▼$1.3550-Day Range$1.30▼$2.1152-Week Range$0.84▼$2.99Volume124,300 shsAverage Volume434,115 shsMarket Capitalization$56.68 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Aligos Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside203.0% Upside$4.00 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.75) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector309th out of 983 stocksBiological Products, Except Diagnostic Industry51st out of 161 stocks 3.3 Analyst's Opinion Consensus RatingAligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Aligos Therapeutics has a forecasted upside of 203.0% from its current price of $1.32.Amount of Analyst CoverageAligos Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.93% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently increased by 16.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aligos Therapeutics is -0.80. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aligos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.80% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.53% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($1.75) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aligos Therapeutics (NASDAQ:ALGS) StockAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Read More Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALGS Stock News HeadlinesMarch 14, 2023 | msn.comAligos Therapeutics Earnings Perspective: Return On Capital EmployedMarch 9, 2023 | finance.yahoo.comAligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue EstimatesMarch 20, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 9, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsMarch 8, 2023 | msn.comA Preview Of Aligos Therapeutics's EarningsMarch 1, 2023 | finance.yahoo.comAligos Therapeutics to Announce Fourth Quarter Results March 9, 2023February 23, 2023 | seekingalpha.comALGS Aligos Therapeutics, Inc.March 20, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 16, 2023 | finance.yahoo.comAligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverFebruary 14, 2023 | finance.yahoo.comAligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverFebruary 10, 2023 | finance.yahoo.comAligos Therapeutics to Present at the SVB Securities Global Biopharma ConferenceFebruary 8, 2023 | finance.yahoo.comAligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024January 23, 2023 | finance.yahoo.comAligos Therapeutics (NASDAQ:ALGS) adds US$18m to market cap in the past 7 days, though investors from a year ago are still down 34%January 16, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)January 6, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For January 6, 2023January 5, 2023 | finance.yahoo.comAligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009December 14, 2022 | finance.yahoo.comAligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)December 8, 2022 | finance.yahoo.comAligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART MeetingNovember 4, 2022 | technews.tmcnet.comAligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD's The Liver Meeting® 2022November 4, 2022 | finance.yahoo.comAligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022November 4, 2022 | finance.yahoo.comAligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022November 3, 2022 | markets.businessinsider.comSVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To KnowNovember 2, 2022 | technews.tmcnet.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial ResultsOctober 21, 2022 | technews.tmcnet.comAligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022October 21, 2022 | finance.yahoo.comAligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALGS Company Calendar Last Earnings11/03/2021Today3/20/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALGS CUSIPN/A CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+203.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,050,000.00 Net Margins-690.63% Pretax Margin-689.87% Return on Equity-74.49% Return on Assets-54.59% Debt Debt-to-Equity RatioN/A Current Ratio4.03 Quick Ratio4.03 Sales & Book Value Annual Sales$13.91 million Price / Sales4.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.43 per share Price / Book0.54Miscellaneous Outstanding Shares42,940,000Free Float36,585,000Market Cap$56.68 million OptionableNot Optionable Beta2.50 Key ExecutivesDr. Lawrence M. Blatt MBA (Age 60)Ph.D., CEO & Chairman Comp: $872.58kDr. Leonid Beigelman Ph.D. (Age 63)Pres & Director Comp: $702.25kDr. Julian A. Symons DPHIL (Age 61)Exec. VP & Chief Scientific Officer Comp: $618.82kMs. Lesley Ann Calhoun CPA (Age 56)Exec. VP & CFO Ms. Lucinda Y. Quan J.D. (Age 50)Exec. VP, Chief Bus. Officer & Gen. Counsel Kristina EngesethExec. Director and Head of People & CultureMr. John Fry (Age 59)Exec. VP of Clinical Devel. Dr. Matthew W. McClure M.D. (Age 50)Exec. VP & Chief Medical Officer Dr. Sushmita M. Chanda DABT (Age 56)Ph.D., Exec. VP of Translational Safety Sciences Dr. David B. Smith Ph.D.Exec. VP & Head of Chemical OperationsMore ExecutivesKey CompetitorsAziyo BiologicsNASDAQ:AZYOaTyr PharmaNASDAQ:LIFETCR2 TherapeuticsNASDAQ:TCRRPassage BioNASDAQ:PASGSenti BiosciencesNASDAQ:SNTIView All CompetitorsInstitutional OwnershipTang Capital Management LLCBought 1,142,225 shares on 2/15/2023Ownership: 6.577%Millennium Management LLCBought 39,188 shares on 2/15/2023Ownership: 0.867%Point72 Asset Management L.P.Sold 11,140 shares on 2/14/2023Ownership: 2.116%Two Sigma Investments LPSold 34,008 shares on 2/14/2023Ownership: 0.211%Geode Capital Management LLCBought 9,440 shares on 2/13/2023Ownership: 0.467%View All Institutional Transactions ALGS Stock - Frequently Asked Questions Should I buy or sell Aligos Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALGS shares. View ALGS analyst ratings or view top-rated stocks. What is Aligos Therapeutics' stock price forecast for 2023? 4 brokers have issued 1-year price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price. View analysts price targets for ALGS or view top-rated stocks among Wall Street analysts. How have ALGS shares performed in 2023? Aligos Therapeutics' stock was trading at $0.9529 at the beginning of the year. Since then, ALGS shares have increased by 38.5% and is now trading at $1.32. View the best growth stocks for 2023 here. Are investors shorting Aligos Therapeutics? Aligos Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 853,900 shares, an increase of 16.2% from the February 13th total of 735,100 shares. Based on an average trading volume of 402,600 shares, the days-to-cover ratio is presently 2.1 days. Approximately 2.9% of the shares of the stock are sold short. View Aligos Therapeutics' Short Interest. When is Aligos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ALGS earnings forecast. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The business had revenue of $1.54 million for the quarter. Aligos Therapeutics had a negative net margin of 690.63% and a negative trailing twelve-month return on equity of 74.49%. When did Aligos Therapeutics IPO? (ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. What is Aligos Therapeutics' stock symbol? Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS." Who are Aligos Therapeutics' major shareholders? Aligos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (6.58%), Point72 Asset Management L.P. (2.12%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.87%), New York Life Investment Management LLC (0.62%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Thomas Woiwode and Vivo Capital Fund Viii, LP. View institutional ownership trends. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aligos Therapeutics' stock price today? One share of ALGS stock can currently be purchased for approximately $1.32. How much money does Aligos Therapeutics make? Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $56.68 million and generates $13.91 million in revenue each year. The company earns $-96,050,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. How can I contact Aligos Therapeutics? The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com. This page (NASDAQ:ALGS) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.